{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:46:27Z","timestamp":1785897987036,"version":"3.56.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304978"],"award-info":[{"award-number":["82304978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305220"],"award-info":[{"award-number":["82305220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374368"],"award-info":[{"award-number":["82374368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108310","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:28:31Z","timestamp":1781911711000},"page":"108310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mapping BAFF\/APRIL dependency across autoimmune diseases: A mechanistic framework for understanding differential therapeutic responses"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4424-8613","authenticated-orcid":false,"given":"Wen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-9610","authenticated-orcid":false,"given":"Hongliang","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108310_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell\u2013directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.immuni.2021.07.015","article-title":"The unique biology of germinal center B cells","volume":"54","author":"Young","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2026.108310_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114084","article-title":"Identifying potential mechanism and targets for treatment of tertiary lymphoid structure in lupus nephritis based on bioinformatics analysis","volume":"148","author":"Zou","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108310_bib4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib5","article-title":"Advances of regulatory B cells in autoimmune diseases","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib6","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.3390\/ijms222413560","article-title":"B cells in primary membranous nephropathy: escape from immune tolerance and implications for patient management","volume":"22","author":"So","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108310_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and regulatory B cells in immune-mediated kidney disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2026.108310_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100011","article-title":"Paradoxical role of Breg-inducing cytokines in autoimmune diseases","volume":"2","author":"Mohd Jaya","year":"2019","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108310_bib9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2026.108310_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112769","article-title":"B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges","volume":"140","author":"Wu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108310_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/cei.13024","article-title":"B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets","volume":"190","author":"Becerra","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1593338","article-title":"B cell development: transcriptional regulation and immunological mechanisms in homeostasis","volume":"16","author":"G\u00f3mez-Manr\u00edquez","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","article-title":"S.G. Tangye, The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers","volume":"4","author":"Mackay","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108310_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103329","article-title":"The emerging role of BLyS\/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential","volume":"149","author":"Hu","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108310_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1050528","article-title":"B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease","volume":"14","author":"Giordano","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fonc.2020.00827","article-title":"The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer","volume":"10","author":"Kampa","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2026.108310_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib19","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL system in cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108310_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fimmu.2013.00509","article-title":"Non-canonical NF-\u03baB signaling initiated by BAFF influences B cell biology at multiple junctures","volume":"4","author":"Gardam","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored?","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2026.108310_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.phrs.2026.108310_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ijms21030779","article-title":"High Pretransplant BAFF levels and B-cell subset polarized towards a memory phenotype as predictive biomarkers for antibody-mediated rejection","volume":"21","author":"Irure-Ventura","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108310_bib28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108310_bib29","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.173.4.2245","article-title":"TNF Family Member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology","volume":"173","author":"Sasaki","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108310_bib31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ni.1914","article-title":"The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88","volume":"11","author":"He","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938240","article-title":"Multi-omics analysis of na\u00efve B cells of patients harboring the C104R mutation in TACI","volume":"13","author":"Ramirez","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2026.108310_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1523392","article-title":"Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Poznyak","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib36","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/keaa484","article-title":"New biomarkers in SLE: from bench to bedside","volume":"59","author":"Capecchi","year":"2020","journal-title":"Rheumatol. (Oxf. )"},{"key":"10.1016\/j.phrs.2026.108310_bib37","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108310_bib38","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/ijms21103463","article-title":"Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus","volume":"21","author":"Parodis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108310_bib39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.2100623","article-title":"APRIL drives a coordinated but diverse response as a foundation for plasma cell longevity","volume":"209","author":"Stephenson","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2026.108310_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2026.108310_bib42","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.1600017","article-title":"Cutting edge: BAFF promotes autoantibody production via TACI-dependent activation of transitional B cells","volume":"196","author":"Jacobs","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep35673","article-title":"Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling","volume":"6","author":"Wensveen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108310_bib44","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191393","article-title":"Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival","volume":"218","author":"M\u00fcller-Winkler","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111019","article-title":"BAFFR activates PI3K\/AKT signaling in human naive but not in switched memory B cells through direct interactions with B cell antigen receptors","volume":"39","author":"Sevdali","year":"2022","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108310_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00011-023-01838-5","article-title":"Imbalance of T follicular helper cell subsets trigger the differentiation of pathogenic B cells in idiopathic membranous nephropathy","volume":"73","author":"Deng","year":"2024","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.phrs.2026.108310_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.183400","article-title":"BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108310_bib48","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1681\/ASN.0000000000000202","article-title":"Tertiary lymphoid tissues are microenvironments with intensive interactions between immune cells and proinflammatory parenchymal cells in aged kidneys","volume":"34","author":"Yoshikawa","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2026.108310_bib49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","article-title":"The roles of tertiary lymphoid structures in chronic diseases","volume":"19","author":"Sato","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2026.108310_bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108310_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/leu.2015.174","article-title":"The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells","volume":"30","author":"Saulep-Easton","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2026.108310_bib52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fimmu.2019.00788","article-title":"the right place, at the right time: spatiotemporal conditions determining plasma cell survival and function","volume":"10","author":"Lindquist","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib53","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404309121","article-title":"Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues","volume":"121","author":"Eslami","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2026.108310_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109689","article-title":"TACI and endogenous APRIL in B cell maturation","volume":"253","author":"Garcia-Carmona","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib56","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.phrs.2026.108310_bib57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","article-title":"Targeting APRIL in the treatment of glomerular diseases","volume":"106","author":"Cheung","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2026.108310_bib58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14728222.2014.888415","article-title":"Therapeutic targeting of the BAFF\/APRIL axis in systemic lupus erythematosus","volume":"18","author":"Stohl","year":"2014","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2026.108310_bib59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2026.108310_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored?","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2026.108310_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2021.06.009","article-title":"Function, occurrence and inhibition of different forms of BAFF","volume":"71","author":"Eslami","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib62","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.yexcr.2011.02.005","article-title":"BAFF inhibition: a new class of drugs for the treatment of autoimmunity","volume":"317","author":"Liu","year":"2011","journal-title":"Exp. Cell. Res."},{"key":"10.1016\/j.phrs.2026.108310_bib63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40259-025-00742-0","article-title":"Targeting CD20 for B-cell depletion in autoimmune kidney disease: next generation","volume":"39","author":"Yandian","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.phrs.2026.108310_bib64","first-page":"1259","article-title":"Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment","volume":"43","author":"Sun","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib65","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib66","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2025-0390.PV262","article-title":"Ianalumab\u2019s dual mode of action: targeting b cells through enhanced b cell depletion and blockade of b cell-activating factor receptor signaling","author":"Wioland","year":"2025","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108310_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108310_bib69","article-title":"BAFF\/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study","volume":"12","author":"Huang","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis & Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib71","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"Van Vollenhoven","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib72","article-title":"A Phase 3 trial of atacicept in patients with IgA nephropathy","author":"Lafayette","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib73","doi-asserted-by":"crossref","first-page":"10845","DOI":"10.3390\/ijms251910845","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108310_bib74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren\u2019s syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2026.108310_bib75","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.515","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.phrs.2026.108310_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106838","article-title":"Alterations of B-cell subsets in peripheral blood from adult patients with idiopathic membranous nephropathy","volume":"266","author":"Wang","year":"2024","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.phrs.2026.108310_bib78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2026.108310_bib79","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ard.2025.11.015","article-title":"B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment","volume":"85","author":"Agmon-Levin","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib80","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib81","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis & Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1423035","article-title":"Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib84","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108310_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533093","article-title":"Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL\/6N mice","volume":"16","author":"Rinaldi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib86","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib87","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/jcm11102810","article-title":"New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib88","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis & Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib89","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2026.108310_bib90","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2026.108310_bib91","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib92","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/art.21138","article-title":"BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus","volume":"52","author":"Stohl","year":"2005","journal-title":"Arthritis & Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib93","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/art.39710","article-title":"Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry","volume":"68","author":"Malkiel","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib95","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramsk\u00f6ld","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.108310_bib96","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108310_bib97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fimmu.2020.00433","article-title":"Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders","volume":"11","author":"Kaegi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib98","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104389","article-title":"Biologics in Sj\u00f6gren\u2019s syndrome","volume":"147","author":"Skarlis","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108310_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102712","article-title":"Mapping the B-cell axis in Sj\u00f6gren\u2019s disease: repertoire, microenvironment, and potential routes to precision treatment","volume":"98","author":"Chatzis","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib101","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","article-title":"International task force on nomenclature of Sj\u00f6gren disease, 2023 International Rome consensus for the nomenclature of Sj\u00f6gren disease","volume":"21","author":"Ramos-Casals","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib102","unstructured":"Ianalumab demonstrates significant reduction in disease activity in patients with Sj\u00f6gren\u2019s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2), ACR Meeting Abstracts (n.d.). \u3008https:\/\/acrabstracts.org\/abstract\/ianalumab-demonstrates-significant-reduction-in-disease-activity-in-patients-with-sjogrens-disease-efficacy-and-safety-results-from-two-global-phase-3-randomized-placebo-controlled-double-blind-s\/\u3009 (accessed May 19, 2026)."},{"key":"10.1016\/j.phrs.2026.108310_bib103","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.phrs.2026.108310_bib104","first-page":"54","article-title":"IgA nephropathy: beyond the half-century","volume":"60","author":"Shimizu","year":"2023","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.phrs.2026.108310_bib105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B Cells in IgA nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"JASN"},{"key":"10.1016\/j.phrs.2026.108310_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.715253","article-title":"An update on targeted treatment of IgA nephropathy: an autoimmune perspective","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108310_bib107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib108","article-title":"Sibeprenlimab in IgA Nephropathy \u2014 interim analysis of a phase 3 trial","author":"Perkovic","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib109","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2026.108310_bib110","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa2514415","article-title":"Telitacicept for IgA nephropathy \u2014 interim analysis of a phase 3 trial","volume":"394","author":"Lv","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib111","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ekir.2025.10.029","article-title":"AIS-D03 RUBY-3 Study Group, Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy","volume":"11","author":"Madan","year":"2026","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.phrs.2026.108310_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8483650","article-title":"Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy","volume":"2019","author":"Netti","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.phrs.2026.108310_bib113","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108310_bib114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cell.2019.03.037","article-title":"Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10","volume":"177","author":"Rojas","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108310_bib115","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/ijms24032336","article-title":"Dual Role of B Cells in Multiple Sclerosis","volume":"24","author":"Kumar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108310_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109870","article-title":"B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation","volume":"258","author":"Asplund H\u00f6gelin","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib117","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"Van Vollenhoven","year":"2011","journal-title":"Arthritis & Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib118","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2014-207090","article-title":"Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib119","unstructured":"Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study, ACR Meeting Abstracts (n.d.). \u3008https:\/\/acrabstracts.org\/abstract\/telitacicept-a-human-recombinant-fusion-protein-targeting-and-neutralizing-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-in-rheumatoid-arthritis-ra-patients-with-an-in\/\u3009 (accessed May 19, 2026)."},{"key":"10.1016\/j.phrs.2026.108310_bib120","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"BLISS-52 Study Group, BLISS-76 Study Group, Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2026.108310_bib121","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.43059","article-title":"Safety and Efficacy of Ianalumab in Patients With Sj\u00f6gren\u2019s Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study","volume":"77","author":"D\u00f6rner","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1759720X15586782","article-title":"B-cell survival factors in autoimmune rheumatic disorders","volume":"7","author":"Morais","year":"2015","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib123","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib124","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial","volume":"67","author":"Van Vollenhoven","year":"2015","journal-title":"Arthritis & Rheumatol."},{"key":"10.1016\/j.phrs.2026.108310_bib125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"on behalf of the ORIGIN Phase 2b Investigators, Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"JASN"},{"key":"10.1016\/j.phrs.2026.108310_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103837","article-title":"Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab","volume":"24","author":"Frade-Sosa","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2026.108310_bib127","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib128","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib129","doi-asserted-by":"crossref","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2026.108310_bib130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/annrheumdis-2023-eular.1727","article-title":"OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS\/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY","volume":"82","author":"Wang","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib131","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000037","article-title":"Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study","volume":"1","author":"Schiff","year":"2015","journal-title":"RMD Open."},{"key":"10.1016\/j.phrs.2026.108310_bib132","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","article-title":"De novo lupus nephritis during treatment with belimumab","volume":"60","author":"Parodis","year":"2021","journal-title":"Rheumatol. (Oxf. )"},{"key":"10.1016\/j.phrs.2026.108310_bib133","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2072143","article-title":"Belimumab for systemic lupus erythematosus - Focus on lupus nephritis","volume":"18","author":"Pl\u00fc\u00df","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.phrs.2026.108310_bib134","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1681\/ASN.0000000772","article-title":"Targeting B Cells and Plasma Cells in Glomerular Disease","volume":"36","author":"Ahmad","year":"2025","journal-title":"JASN"},{"key":"10.1016\/j.phrs.2026.108310_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117018","article-title":"B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives","volume":"239","author":"Chen","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108310_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.1353","article-title":"POS0540 reduction of b cell subsets, autoantibodies and disease-relevant pathways in Ianalumab treated patients with systemic lupus erythematosus: findings from a phase 2 clinical trial","author":"D\u00f6rner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib137","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12703","article-title":"A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus","volume":"183","author":"Szab\u00f3","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib138","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib139","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2026.108310_bib140","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108310_bib141","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108310_bib142","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108310_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108310_bib144","article-title":"Research progress on regulatory B cells in systemic lupus erythematosus","volume":"2019","author":"Wang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2026.108310_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.183400","article-title":"BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108310_bib146","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1084\/jem.20030495","article-title":"Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice","volume":"198","author":"Rahman","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2026.108310_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904415","article-title":"A comparative study of adjuvants effects on neonatal plasma cell survival niche in bone marrow and persistence of humoral immune responses","volume":"13","author":"Aradottir Pind","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib148","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2025.12.004","article-title":"BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape","author":"Sezer","year":"2025","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.phrs.2026.108310_bib149","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"eBioMedicine"},{"key":"10.1016\/j.phrs.2026.108310_bib150","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib151","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108310_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1622395","article-title":"Exploring immunological alterations of B cells in peripheral immunity via single-cell RNA sequencing: insights into primary membranous nephropathy","volume":"16","author":"Lu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib153","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","article-title":"Inhibition of membrane-bound BAFF by the anti-BAFF antibody belimumab","volume":"9","author":"Kowalczyk-Quintas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108310_bib154","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China","volume":"9","author":"Tan","year":"2023","journal-title":"Kidney Dis. (Basel)"},{"key":"10.1016\/j.phrs.2026.108310_bib155","doi-asserted-by":"crossref","DOI":"10.1186\/ar2959","article-title":"B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin","volume":"12","author":"Dillon","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2026.108310_bib156","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ekir.2022.01.121","article-title":"POS-109 interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.phrs.2026.108310_bib157","doi-asserted-by":"crossref","first-page":"16330","DOI":"10.1074\/jbc.M115.661405","article-title":"Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties","volume":"290","author":"Schuepbach-Mallepell","year":"2015","journal-title":"J. Biol. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:05:10Z","timestamp":1785895510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":157,"alternative-id":["S1043661826002252"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108310","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping BAFF\/APRIL dependency across autoimmune diseases: A mechanistic framework for understanding differential therapeutic responses","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108310"}}